Index trend and stocks in action February 08, 2019
Index trend and stocks in action February 08, 2019

Index trend and stocks in action February 08, 2019

Karan Dsij Article rating: 5.0

The top of a Doji session which stands at 11,118 is likely to act as a resistance level. However, if the high of the Doji is exceeded, then the Nifty uptrend should continue towards the level of 11,180. Stocks in news: Raymond, Varun Beverages, Ceat, Pricol, Jet Airways and Shriram EPC.

Markets to open weak following negative global cues
Markets to open weak following negative global cues

Markets to open weak following negative global cues

Karan Dsij Article rating: 5.0

The mood of the global markets turned jittery as global growth concerns returned to haunt the markets and also, reports indicated that President Donald Trump did not expect to meet his Chinese counterpart Xi Jinping before the March deadline for trade war negotiations. Considering these factors, we may see initial weakness in the Indian markets. The SGX Nifty suggests that Nifty may open around 11,073, down by 21 points. Some of the key stocks such as BPCL, Engineers India, M&M, REC and Tata Steel will announce their quarterly earnings. 

Auto sector growth to be cautiously optimistic
Auto sector growth to be cautiously optimistic

Auto sector growth to be cautiously optimistic

Aakash Makhija Article rating: 5.0
For FY21, however, their view is unequivocally for a temporary drop in volume forced by an 8-10 per cent increase in prices across market segments due to the BSVI roll out. The catalyst could be tax cuts and/or a practical scrappage policy by the Government.
Tata Motors reports losses of Rs. 26,992.54 crore
Tata Motors reports losses of Rs. 26,992.54 crore

Tata Motors reports losses of Rs. 26,992.54 crore

Dnyanada Kulkarni Article rating: 3.8

For the quarter ended December 2018, Tata Motors reported staggering losses of Rs. 26,992.54 crore as its luxury car unit, Jaguar Land Rover (JLR) continued to struggle.

Q3FY19: Apex Frozen PAT down 39.72 per cent
Q3FY19: Apex Frozen PAT down 39.72 per cent

Q3FY19: Apex Frozen PAT down 39.72 per cent

Advait Dharmadhikari Article rating: 3.5

The company reported a PAT of Rs. 11.35 crore with an EPS of Rs. 3.63 for the quarter ended December 2018 as against Rs. 18.83 crore with an EPS of Rs. 6.02 per share for the corresponding quarter last year, registering a degrowth of 39.72 per cent per cent.

Bajaj Electrical shines on back of Q3 results
Bajaj Electrical shines on back of Q3 results

Bajaj Electrical shines on back of Q3 results

Amir Shaikh Article rating: 5.0

The PAT for the quarter came in at Rs. 63.92 crore, yoy increase of 73.6 per cent. Finance cost for the quarter jumped 132 per cent yoy to Rs. 33.3 crore. 

How India's credibility is at stake in the crypto world?
How India's credibility is at stake in the crypto world?

How India's credibility is at stake in the crypto world?

Gayathri Udyawar Article rating: 3.8

Much of the bitcoin, cryptocurrency frenzy had fizzled out in 2018, but many investors or so-called early adopters still hold hope in the phenomenon dubbed as the currency of the digital age. Now there is a major twist in the cryptocurrency tale and all that happened very close to us, read on to know.

Manappuram Q3 net profit up 42 per cent, stock gains
Manappuram Q3 net profit up 42 per cent, stock gains

Manappuram Q3 net profit up 42 per cent, stock gains

Shohini Nath Article rating: 5.0

Manappuram Finance Limited has declared a good set of numbers for third quarter FY19. Shares of Mannappuram reached an intraday high of Rs. 104.15 per share on the BSE on Thursday.  

Is the thumb rule 100 minus age relevant today?
Is the thumb rule 100 minus age relevant today?

Is the thumb rule 100 minus age relevant today?

Henil Shah Article rating: 5.0

In asset allocation, 100 minus age is one of the basic thumb rules. Let’s find out if this rule is valid in today’s circumstances?

CIPLA receives approval from US FDA
CIPLA receives approval from US FDA

CIPLA receives approval from US FDA

Aakash Makhija Article rating: 5.0
Cipla’s Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly’s Adcirca. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.
RSS
First26922693269426952697269927002701Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR